ReviewMaterials today. Bio2026
Advances in 3D bioprinting of immunoregulatory biomaterials for bone regeneration.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone defects caused by trauma, infection, tumour resection, and degenerative diseases remain major clinical challenges because successful regeneration requires coordinated regulation of inflammation, vascularisation, osteogenesis, and bone remodeling. Advances in osteoimmunology have demonstrated that immune responses are integral to each stage of bone healing, shifting biomaterial design from passive biocompatibility towards active and temporally coordinated immunomodulation. Three dimensional bioprinting provides a versatile platform for integrating material, structural, cellular, and biochemical cues within spatially defined constructs, thereby offering new opportunities to regulate the osteoimmune microenvironment. In this review, we first summarise the immune processes and key immune cell populations involved in the inflammatory, proliferative, and remodeling stages of bone repair, and discuss the major bioprinting technologies and bioink design principles relevant to immunoregulatory bone regeneration. We then examine how material composition, structural and surface cues, and biologically active components, including stem cells, cytokines, exosomes, and decellularised extracellular matrix, regulate immune cell states and their interactions with vascular and osteogenic processes. Particular emphasis is placed on moving beyond static macrophage polarisation towards multicellular, stage specific, and spatiotemporally controlled immunoregulation. Finally, current challenges and future directions are discussed, including responsive and multifunctional bioinks, controlled degradation and delivery, mechanistic evaluation, manufacturing standardisation, and clinical translation. Collectively, immunoregulatory bioprinting provides a promising framework for developing bone regenerative constructs that more closely coordinate with the dynamic biology of tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.